Source ID: D24
Original URL: https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html
Title (supplied): AstraZeneca breaks ground on Singapore ADC facility
Source date (retained): 2024-11-07
Data date (retained): 2024-11-07
Checked at: 2026-10-07T18:42:41+08:00
Timezone: Asia/Taipei
Checked-at meaning: current review of returned public web-tool extraction; not the historical network-fetch timestamp.
Retrieval mode: public_web_tool_readback_prior_ref; prior saved web_ref was opened and returned the specified original public URL.
Prior web ref: turn35view4
Current web ref: turn132view0
Read level: relevant primary-source paragraphs in web text extraction; complete original HTML/PDF bytes not saved or hashed.
Original network read time: null; not exposed by the tool. Original artifact SHA256: null.
Locator: AstraZeneca Singapore construction release; retrieved lines 182–200, especially 195 and 200.
Minimum verbatim excerpts (aggregate <=25 English words):
- $1.5 billion USD facility
- operationally ready by 2029
Excerpt word count: 8
Factual extraction (values, dates, statuses; not additional prose quotations):
[
  {
    "field": "release_date",
    "original_value": "7 November 2024",
    "unit_or_role": "calendar date",
    "locator": "L182"
  },
  {
    "field": "planned_investment",
    "original_value": 1.5,
    "unit_or_role": "USD billion",
    "locator": "L195"
  },
  {
    "field": "target_operational_year",
    "original_value": 2029,
    "unit_or_role": "calendar year; target, not achieved operation",
    "locator": "L184, L195"
  },
  {
    "field": "manufacturing_stages",
    "original_value": [
      "antibody production",
      "chemotherapy drug and linker synthesis",
      "conjugation",
      "vial filling"
    ],
    "unit_or_role": "planned facility scope",
    "locator": "L200"
  }
]
Support scope: Construction investment and 2029 target are explicit. The planned site covers antibody production, drug/linker synthesis, conjugation and vial filling; future capacity is not current delivered supply. Old ticker boilerplate is not reused as current listing evidence.
Precise gap: No additional source-specific factual gap found within the assigned contribution; multi-source rows retain their other citations.
Source/data dates are supplied baseline metadata, not replaced by this check time. No alternate route, login, headers, private endpoint or payment used.
This small evidence record is an excerpt/factual extraction, not a saved full article.